Liminal Biosciences Total Liabilities

Liminal Biosciences (LMNL) currently reports a total liabilities of $10M as of June 2023. That compares with $53M in the prior-year period — down 80.6% year over year. Use the charts on this page to explore Liminal Biosciences's total liabilities history and peer comparisons.

Liminal Biosciences's total liabilities decreased from $53M to $10M — a 80.6% year-over-year decrease (period ending June 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Liminal Biosciences reported $10M in total liabilities as of June 2023. That compares with $53M in the prior-year period — down 80.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total liabilities of $10M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Liminal Biosciences, and consider following LMNL for alerts when major investors trade the stock.

Liminal Biosciences is classified in the Healthcare sector. On total liabilities, it currently shows $10M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing LMNL with unrelated industries.